Immune thrombocytopenia (ITP) is a rare blood disorder where the immune system mistakenly attacks platelets, leading to easy bruising and bleeding. While treatment may not be needed for everyone, various therapeutic options exist to help manage symptoms and raise platelet counts to safe levels, with ongoing research exploring new approaches that target different aspects of the disease.

Managing a Complex Blood Disorder Through Personalized Care

When someone is diagnosed with immune thrombocytopenia, the primary goals of treatment focus on bringing platelet counts to a level that prevents dangerous bleeding while minimizing side effects and maintaining quality of life. Not everyone with ITP needs treatment right away. Many patients, especially those without symptoms or severe bleeding, may only need careful monitoring through regular platelet checks. The decision to begin treatment depends on how low the platelet count has dropped, whether bleeding symptoms are present, and individual patient factors such as age, lifestyle, and other health conditions.^[1]

Treatment approaches vary significantly depending on the stage of the disease. In children, ITP often appears suddenly after a viral infection but frequently resolves on its own within six to twelve months without any medical intervention. Adults, however, tend to experience a more gradual onset, and the condition often becomes chronic, lasting a year or more. This means adults are more likely to need ongoing treatment to manage their platelet levels.^[2]

Medical societies and expert groups have developed clinical guidelines that help doctors choose the most appropriate treatments for each patient. These recommendations are based on extensive research and aim to balance effectiveness with safety. Beyond traditional therapies that have been used for decades, researchers are actively testing new drugs in clinical trials. These experimental treatments target different mechanisms that cause ITP, offering hope for patients who don’t respond well to standard options or who experience troubling side effects.^[3]

Standard Treatment Approaches for Immune Thrombocytopenia

When treatment becomes necessary, doctors typically start with well-established medications that have been used for many years. The most common first-line therapy involves corticosteroids, which are drugs that temporarily suppress the immune system. Prednisone is the corticosteroid most frequently prescribed as an oral medication, while high-dose dexamethasone offers another option. These medications work by slowing down the rate at which the immune system destroys platelets. An important additional benefit is that corticosteroids may rapidly improve the integrity of blood vessel walls, helping to reduce bleeding and bruising even before platelet counts rise significantly.^[9]

Corticosteroids can raise platelet counts relatively quickly, which makes them particularly valuable when a fast response is needed, such as in patients with life-threatening bleeding or those who need urgent surgery. However, these drugs are not intended for long-term use. Prolonged treatment with corticosteroids can lead to significant side effects including increased risk of infections, elevated blood sugar levels that may lead to diabetes, bone thinning (osteoporosis), weight gain, mood changes, and sleep disturbances. For this reason, doctors typically try to reduce the dose gradually once platelet counts reach a safe level.^[9]

Another important first-line treatment is intravenous immunoglobulin, commonly called IVIG. This medication consists of antibodies collected from thousands of blood donors. When given through a vein, IVIG can quickly raise platelet counts, usually within a few days. It works by temporarily blocking the immune system’s ability to destroy platelets. IVIG is particularly useful when a rapid increase in platelets is critical, such as before emergency surgery or in cases of severe bleeding. The main drawbacks include the need for intravenous administration, which can take several hours, and common side effects such as headache, fever, and fatigue. The effects are also temporary, typically lasting only a few weeks.^[9]

For patients who are Rh-positive and still have their spleen, anti-D immunoglobulin (also called anti-RhD or RhIG) provides another option. This medication is given intravenously and offers similar benefits to IVIG but with potentially fewer side effects, easier administration, and lower cost. However, it only works in people with Rh-positive blood who haven’t had their spleen removed. The most significant concern with anti-D immunoglobulin is that it can cause destruction of red blood cells, leading to anemia (a condition where the body doesn’t have enough healthy red blood cells to carry oxygen). This treatment should not be used if a patient’s hemoglobin level is already low.^[12]

When initial treatments don’t produce lasting results, or when patients cannot tolerate long-term corticosteroids, second-line therapies become necessary. Thrombopoietin receptor agonists, or TPO-RAs, represent a major advancement in ITP treatment. These drugs work differently from immune-suppressing medications. Instead of trying to stop the destruction of platelets, they stimulate the bone marrow to produce more platelets. Two main medications in this class are eltrombopag (taken as an oral tablet) and romiplostim (given as an injection under the skin once weekly). These drugs can maintain platelet counts at safe levels for extended periods and are generally well-tolerated. They don’t work immediately—it typically takes one to two weeks to see an increase in platelets—but they can be used for chronic management.^[11]

Rituximab is another second-line option. This drug is a monoclonal antibody, a type of laboratory-made protein that targets specific immune cells called B cells, which produce the antibodies that attack platelets. By reducing the number of these B cells, rituximab can help restore normal platelet counts. The medication is given through a vein, usually in a series of infusions. While many patients respond well to rituximab, the effects may not be permanent, and platelet counts can drop again months or years later. Side effects during infusion can include fever, chills, and drops in blood pressure, though these are usually manageable.^[13]

Surgical removal of the spleen, called splenectomy, has historically been a definitive treatment for ITP. The spleen is the organ where much of the platelet destruction occurs, so removing it can dramatically improve platelet counts in many patients. Studies show that about two-thirds of patients achieve lasting remission after splenectomy. However, surgery comes with risks including bleeding, infection, and blood clots. More importantly, people without spleens have a lifelong increased risk of severe infections from certain bacteria. Due to these concerns and the availability of newer medications, splenectomy is now typically reserved for patients who haven’t responded to multiple drug treatments.^[9]

Other immunosuppressive medications may be used when standard treatments fail. Azathioprine, mycophenolate mofetil, and cyclosporine are drugs that suppress various parts of the immune system. In some regions, particularly in Asian countries, cyclosporine has shown good results as a second-line treatment, often used in combination with other therapies. These medications require careful monitoring because they can increase infection risk and may affect kidney function or blood counts.^[12]

Innovative Treatments Being Tested in Clinical Trials

As scientists have learned more about the complex immune mechanisms that cause ITP, pharmaceutical companies and research institutions have developed new drugs that target these specific pathways. Many of these experimental treatments are currently being evaluated in clinical trials around the world, offering potential options for patients who need alternatives to existing therapies.^[11]

One promising class of drugs under investigation includes spleen tyrosine kinase (Syk) inhibitors. Syk is an enzyme that plays a crucial role in how immune cells recognize and destroy platelets coated with antibodies. By blocking this enzyme, these drugs can reduce platelet destruction. Fostamatinib is the first Syk inhibitor that has completed clinical trials and received approval in the United States and Europe for adult patients with chronic ITP who haven’t responded adequately to other treatments. The medication is taken orally twice daily. In Phase III clinical trials, fostamatinib demonstrated the ability to raise and maintain platelet counts above safe thresholds in patients who had failed multiple prior therapies. Common side effects include diarrhea, elevated blood pressure, and abnormal liver function tests, which require monitoring.^[11]

Bruton’s tyrosine kinase (BTK) inhibitors represent another novel approach. BTK is an enzyme critical for the development and function of B cells, the immune cells that produce antibodies against platelets. By inhibiting BTK, these drugs can reduce the production of the antibodies that destroy platelets. Rilzabrutinib is a BTK inhibitor that has shown encouraging results in clinical trials for ITP. It is taken orally and has demonstrated the ability to increase platelet counts with a generally favorable safety profile. This medication has received approval in the United States as a second-line treatment option for adults with chronic ITP. Clinical studies are ongoing to further define its role in ITP management and to evaluate its long-term effectiveness.^[11]

An entirely different strategy involves targeting the neonatal Fc receptor, often abbreviated as FcRn. This receptor is responsible for recycling antibodies in the body, extending their lifespan. By blocking FcRn, drugs can accelerate the removal of harmful antibodies from circulation, including the ones that attack platelets in ITP. Several FcRn inhibitors are currently in Phase II and Phase III clinical trials. These medications work for various antibody-mediated autoimmune conditions, not just ITP. The advantage of this approach is that it broadly reduces pathogenic antibodies without permanently affecting the immune system’s ability to respond to infections. Early trial results have shown increases in platelet counts with acceptable side effects, though long-term data is still being collected.^[11]

Researchers are also exploring drugs that prevent platelet desialylation. Normally, platelets have sugar molecules called sialic acids on their surface. When these are removed—a process called desialylation—the platelets are recognized as old or damaged and are rapidly cleared from circulation by the liver. In ITP, this process may be inappropriately activated. Investigational drugs that inhibit platelet desialylation aim to keep the protective sugar coating intact, preventing premature platelet removal. These treatments are still in early-phase clinical trials, but preliminary data suggests they may offer a unique way to maintain platelet counts without broadly suppressing immunity.^[11]

Another area of active research involves targeting the classical complement pathway, part of the immune system that can contribute to platelet destruction. The complement system consists of proteins that work together to eliminate pathogens and damaged cells. In ITP, this system may be inappropriately activated against platelets. Drugs that block specific complement proteins are being tested to see if they can reduce platelet destruction through this pathway. Some of these complement inhibitors are already used for other rare blood disorders and are now being evaluated for ITP in clinical trials.^[11]

Therapies targeting plasma cells—the long-lived immune cells that continuously produce antibodies—are also under investigation. While rituximab targets B cells (the precursors to plasma cells), it doesn’t eliminate plasma cells that are already established in the bone marrow. Drugs that can specifically target and remove these antibody-producing plasma cells might provide longer-lasting remissions. Proteasome inhibitors, drugs already used to treat certain cancers like multiple myeloma, work by killing plasma cells and are being tested in ITP patients who have failed standard treatments.^[11]

Many of these clinical trials are being conducted at medical centers across multiple countries, including the United States, various European nations, and other regions worldwide. Eligibility criteria vary by trial but typically include factors such as previous treatment history, current platelet counts, presence of bleeding symptoms, and overall health status. Some trials focus specifically on patients who haven’t responded to standard treatments, while others may accept patients earlier in their treatment journey. Trial locations and enrollment information are regularly updated on clinical trial registries, and patients can work with their doctors to find appropriate studies.^[3]

Most common treatment methods

• Corticosteroids
  • Prednisone taken orally as first-line therapy to suppress immune system and slow platelet destruction
  • High-dose dexamethasone as an alternative corticosteroid option
  • Rapid improvement of blood vessel integrity to reduce bleeding even before platelet counts rise
  • Temporary use recommended due to side effects including infections, high blood sugar, and bone thinning with long-term use
• Intravenous immunoglobulin (IVIG)
  • Antibodies from donor blood given through a vein to quickly raise platelet counts
  • Works by blocking the immune system’s ability to destroy platelets temporarily
  • Useful when rapid platelet increase is needed, such as before surgery
  • Effects last only a few weeks and require intravenous administration taking several hours
• Anti-D immunoglobulin
  • Alternative to IVIG for Rh-positive patients with intact spleens
  • Easier to administer, fewer side effects, and lower cost than IVIG
  • Can cause red blood cell destruction leading to anemia as most significant side effect
  • Should not be used when hemoglobin levels are already low
• Thrombopoietin receptor agonists (TPO-RAs)
  • Eltrombopag taken orally and romiplostim given as weekly injections
  • Stimulate bone marrow to produce more platelets rather than suppressing immune system
  • Can maintain platelet counts for extended periods as chronic management
  • Takes one to two weeks to see platelet increases, generally well-tolerated
• Rituximab (monoclonal antibody therapy)
  • Targets B cells that produce antibodies attacking platelets
  • Given through a vein in a series of infusions as second-line option
  • Effects may not be permanent with platelet counts potentially dropping again later
  • Side effects during infusion can include fever, chills, and blood pressure drops
• Splenectomy (surgical treatment)
  • Surgical removal of the spleen where much platelet destruction occurs
  • Can achieve lasting remission in about two-thirds of patients
  • Reserved for patients not responding to multiple drug treatments due to surgery risks
  • Lifelong increased risk of severe bacterial infections after spleen removal
• Novel targeted therapies in clinical trials
  • Fostamatinib (spleen tyrosine kinase inhibitor) taken orally, approved for chronic ITP patients who failed other treatments
  • Rilzabrutinib (Bruton’s tyrosine kinase inhibitor) taken orally, approved as second-line treatment for chronic ITP in adults
  • Neonatal Fc receptor inhibitors in Phase II and III trials to accelerate removal of harmful antibodies
  • Complement pathway inhibitors, platelet desialylation inhibitors, and plasma cell targeting therapies under investigation
• Immunosuppressive medications
  • Azathioprine, mycophenolate mofetil, and cyclosporine used when standard treatments fail
  • Cyclosporine shows good results as second-line treatment in Asian countries, often in combination therapy
  • Require careful monitoring for increased infection risk and effects on kidney function or blood counts